Last edition
News about "Dupixent "
Sanofi, Regeneron Expand Alliance to Develop Four Long-Acting Antibodies
Sanofi and Regeneron expands their antibody collaboration to develop and commercialise four next-generation long-acting antibodies for immune-mediated diseases.
Dupixent | 03/10/2026 | By News Bureau | 101
European Commission Approves Dupixent for Young Children with Chronic Spontaneous Urticaria
The European Commission has expanded approval of Dupixent to children aged 2–11 with chronic spontaneous urticaria, offering a targeted treatment for those unresponsive to standard antihistamines.
Dupixent | 15/04/2026 | By News Bureau | 168
Dupixent Approval in Japan Boosts Biologics Manufacturing Demand for Sanofi and Regeneron
The Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization to Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), a rare and debilitating skin disorder.
Dupixent | 25/03/2026 | By Darshana | 240
Phase 3 results show Dupixent significantly improved nasal symptoms and sinus health in patients aged six and above with allergic fungal rhinosinusitis, supporting its FDA priority review.
Dupixent | 10/11/2025 | By Dineshwori | 383
EMA Approves Dupixent as First-Ever Targeted Therapy for Patients with COPD
The European Medicines Agency (EMA) has recently announced their approval for Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
Dupixent | 04/07/2024 | By Aishwarya | 673
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy